Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt No Debt
XNPT's Cash to Debt is ranked higher than
89% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. XNPT: No Debt )
XNPT' s 10-Year Cash to Debt Range
Min: 23.99   Max: No Debt
Current: No Debt

Equity to Asset 0.79
XNPT's Equity to Asset is ranked higher than
82% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. XNPT: 0.79 )
XNPT' s 10-Year Equity to Asset Range
Min: -1.59   Max: 0.88
Current: 0.79

-1.59
0.88
F-Score: 6
Z-Score: 5.10
M-Score: 2.40
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -118.54
XNPT's Operating margin (%) is ranked higher than
70% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. XNPT: -118.54 )
XNPT' s 10-Year Operating margin (%) Range
Min: -5504.8   Max: 18.25
Current: -118.54

-5504.8
18.25
Net-margin (%) -119.13
XNPT's Net-margin (%) is ranked higher than
70% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. XNPT: -119.13 )
XNPT' s 10-Year Net-margin (%) Range
Min: -4876   Max: 24.77
Current: -119.13

-4876
24.77
ROE (%) -58.01
XNPT's ROE (%) is ranked higher than
66% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. XNPT: -58.01 )
XNPT' s 10-Year ROE (%) Range
Min: -93.4   Max: 27
Current: -58.01

-93.4
27
ROA (%) -42.51
XNPT's ROA (%) is ranked higher than
67% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. XNPT: -42.51 )
XNPT' s 10-Year ROA (%) Range
Min: -127.82   Max: 18.7
Current: -42.51

-127.82
18.7
ROC (Joel Greenblatt) (%) -2014.94
XNPT's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. XNPT: -2014.94 )
XNPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2677.97   Max: 402.46
Current: -2014.94

-2677.97
402.46
Revenue Growth (3Y)(%) 23.60
XNPT's Revenue Growth (3Y)(%) is ranked higher than
92% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. XNPT: 23.60 )
XNPT' s 10-Year Revenue Growth (3Y)(%) Range
Min: -72.6   Max: 126.3
Current: 23.6

-72.6
126.3
EBITDA Growth (3Y)(%) -11.70
XNPT's EBITDA Growth (3Y)(%) is ranked higher than
71% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. XNPT: -11.70 )
XNPT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -54.3   Max: -7.9
Current: -11.7

-54.3
-7.9
EPS Growth (3Y)(%) -12.30
XNPT's EPS Growth (3Y)(%) is ranked higher than
72% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. XNPT: -12.30 )
XNPT' s 10-Year EPS Growth (3Y)(%) Range
Min: -52.3   Max: -7.4
Current: -12.3

-52.3
-7.4
» XNPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

XNPT Guru Trades in Q4 2013

Jim Simons 59,312 sh (New)
PRIMECAP Management 128,000 sh (unchged)
» More
Q1 2014

XNPT Guru Trades in Q1 2014

Steven Cohen 16,300 sh (New)
Paul Tudor Jones 41,668 sh (New)
PRIMECAP Management 128,000 sh (unchged)
Jim Simons Sold Out
» More
Q2 2014

XNPT Guru Trades in Q2 2014

John Burbank 17,817 sh (New)
Paul Tudor Jones Sold Out
PRIMECAP Management 104,000 sh (-18.75%)
» More
Q3 2014

XNPT Guru Trades in Q3 2014

John Burbank Sold Out
PRIMECAP Management 91,000 sh (-12.5%)
» More
» Details

Insider Trades

Latest Guru Trades with XNPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2014-09-30 Sold Out $4.15 - $5.53 $ 8.268%0
John Burbank 2014-06-30 New Buy$3.28 - $5.22 $ 8.294%17817
PRIMECAP Management 2012-06-30 New Buy$4.08 - $6.15 $ 8.259%125000
George Soros 2011-12-31 Sold Out 0.0016%$3.57 - $6.34 $ 8.265%0
George Soros 2011-09-30 Reduce -38.17%$5.95 - $7.72 $ 8.217%16200
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.82
XNPT's P/B is ranked higher than
76% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. XNPT: 4.82 )
XNPT' s 10-Year P/B Range
Min: 1.71   Max: 13.19
Current: 4.82

1.71
13.19
P/S 11.00
XNPT's P/S is ranked higher than
80% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. XNPT: 11.00 )
XNPT' s 10-Year P/S Range
Min: 2.65   Max: 111.17
Current: 11

2.65
111.17
EV-to-EBIT -7.85
XNPT's EV-to-EBIT is ranked lower than
51% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. XNPT: -7.85 )
XNPT' s 10-Year EV-to-EBIT Range
Min: -134.5   Max: 9027.3
Current: -7.85

-134.5
9027.3
Current Ratio 8.71
XNPT's Current Ratio is ranked higher than
84% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. XNPT: 8.71 )
XNPT' s 10-Year Current Ratio Range
Min: 2.31   Max: 12.21
Current: 8.71

2.31
12.21
Quick Ratio 8.61
XNPT's Quick Ratio is ranked higher than
85% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. XNPT: 8.61 )
XNPT' s 10-Year Quick Ratio Range
Min: 2.31   Max: 12.21
Current: 8.61

2.31
12.21

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.99
XNPT's Price/Net Cash is ranked higher than
87% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. XNPT: 5.99 )
XNPT' s 10-Year Price/Net Cash Range
Min: 2.06   Max: 16.33
Current: 5.99

2.06
16.33
Price/Net Current Asset Value 5.81
XNPT's Price/Net Current Asset Value is ranked higher than
86% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. XNPT: 5.81 )
XNPT' s 10-Year Price/Net Current Asset Value Range
Min: 2.06   Max: 16
Current: 5.81

2.06
16
Price/Tangible Book 4.82
XNPT's Price/Tangible Book is ranked higher than
81% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. XNPT: 4.82 )
XNPT' s 10-Year Price/Tangible Book Range
Min: 1.8   Max: 12.9
Current: 4.82

1.8
12.9
Price/Median PS Value 0.76
XNPT's Price/Median PS Value is ranked higher than
91% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. XNPT: 0.76 )
XNPT' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 6.31
Current: 0.76

0.2
6.31
Earnings Yield (Greenblatt) -12.70
XNPT's Earnings Yield (Greenblatt) is ranked higher than
64% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. XNPT: -12.70 )
XNPT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.3   Max: 4492.4
Current: -12.7

1.3
4492.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:LMW.Germany,
XenoPort, Inc., is a Delaware corporation was incorporated on May 19, 1999. The Company is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Its product candidates are prodrugs that are created by modifying the chemical structure of currently marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and metabolism of the parent drug. Its marketed product and each of its product candidates are orally available, patented molecules that address potential markets with clear unmet medical needs. Its marketed product is approved in the United States, where it is known as Horizant Extended-Release Tablets, and in Japan, where it is known as Regnite Extended-Release Tablets. Horizant has been approved by the U.S. Food and Drug Administration, or FDA, for the treatment of moderate-to-severe primary restless legs syndrome, or RLS, in adults and for the management of postherpetic neuralgia, or PHN, in adults. Restless legs syndrome, also known as Willis-Ekbom Disease, is a neurological disorder characterized by an urge to move the legs, usually caused or accompanied by uncomfortable and unpleasant sensations in the legs. PHN is a neuropathic pain syndrome that can follow the healing of an outbreak of herpes zoster, commonly known as shingles. Regnite has been approved by the Japanese Ministry of Health, Labor and Welfare, or MHLW, as a treatment for patients with moderate-to-severe RLS. It is also engaged with third parties for the development of arbaclofen placarbil, or AP, a potential treatment for spasticity in patients with spinal cord injury; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson's disease. With respect to AP, it has decided to terminate further investment in AP as a treatment for spasticity in patients with MS; however, given a previous, successful Phase 2 clinical trial of AP as a potential treatment for spasticity in spinal cord injury patients. XP21279, in the primary analysis of the trial, the improvement with XP21279/carbidopa dosed three times per day was not statistically good than the improvement seen with optimized Sinemet dosed four or five times per day during the double-blind phase of the trial. It has discussed the results of this trial with experts in Parkinson's disease and with regulatory authorities. As a result, it plans to continue development of XP21279 to the extent its resources permit or it enters into collaboration with a third party. The Company faces competition from manufacturers of generic drugs. The Company is subject to regulation by regional, national, state and local agencies, including the Department of Justice, the Federal Trade Commission, the Office of Inspector General of the U.S. Department of Health and Human Services and other regulatory bodies, as well as gov

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK